Extended-release buprenorphine is approved as a once-monthly subcutaneous injection for the treatment of moderate-to-severe ...

Heavy fentanyl users may derive greater benefit from a higher dose of extended-release buprenorphine maintenance therapy, a randomized controlled trial suggests.

Indivior PLC (Nasdaq: INDV) today announced results from a randomized, double-blind clinical trial published in JAMA Network Open. The study found that both the 100-mg and 300-mg monthly maintenance ...

SLOUGH, England and RICHMOND, Va., Dec. 2, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) announced today that new analysis from a 12-month investigation of monthly buprenorphine extended-release ...

A seven-day, extended-release version of buprenorphine — a treatment for opioid use disorder (OUD) that can reduce opioid use and overdose deaths — is safe and effective for people with OUD ...

Fewer than half of commercial and one-fifth of Medicare Advantage formularies covered extended-release buprenorphine in 2021, a new study found. The study, published in the latest issue of Health ...

Credit: Getty Images. Buprenorphine-naloxone may be more cost-effective than extended-release naltrexone as first-line treatment for opioid use disorder. Buprenorphine-naloxone may be more ...

Please provide your email address to receive an email when new articles are posted on . Buprenorphine, especially the extended-release formulation, reduced future ED visits in patients with opioid use ...

Credit: Getty Images. Brixadi (buprenorphine) is an investigational, extended-release weekly and monthly subcutaneous injection for moderate to severe opioid use disorder. The Food and Drug ...

BRIXADI is now available for healthcare settings and pharmacies through a restricted distribution program called the BRIXADI REMS and is administered only by a healthcare professional. PLYMOUTH ...

Credit: Getty Images. The resubmitted NDA was in response to a Complete Response Letter issued by the FDA in December 2021. The Food and Drug Administration (FDA) has accepted the resubmitted New Drug ...